Our study suggests that high FOLH1 expression may be associated with improved OS in both primary and metastatic prostate cancer including liver and bladder metastases but not for patients with certain metastatic tumors such as bone and lung. Here, FOLH1 is linked to metastatic prostate carcinoma.